Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPS01 apalutamide in active surveillance prostate cancer
2017-001700-29Phase 2Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust & The University of Cambridge
- Start
- Jan 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apalutamide in prostate cancer (PCa), sponsored by Cambridge University Hospitals NHS Foundation Trust & The University of Cambridge. Primary endpoint: Physiological response. Started Jan 2018; status: completed.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2017-001700-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001700-29.